[{"id":"quanta-therapeutics","kind":"company","name":"Quanta Therapeutics","route":"/companies/quanta-therapeutics/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/companies.ts","type":"changed","fields":[{"field":"tldr","before":"\"Developer of oral multi-KRAS inhibitors biased to G12D (QTX3034) and G12V (QTX3544), with responses in pancreatic, colorectal, and endometrial cancer.\"","after":"\"Quanta Therapeutics develops oral multi-KRAS inhibitors biased to G12D (QTX3034) and G12V (QTX3544), with responses in pancreatic, colorectal, and endometrial cancer.\""}]},{"id":"quanta-therapeutics","kind":"company","name":"Quanta Therapeutics","route":"/companies/quanta-therapeutics/","commit":"335b83f6e7","date":"2026-09-06","author":"Jude Gomila","message":"Expand companies: Katsutake map imports and 44 frontier oncology companies; add frontier technologies (programmable DNA-targeting, fragmento","file":"src/data/companies.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"hq"},{"field":"country"},{"field":"companyType"},{"field":"website"},{"field":"sections"},{"field":"tldr"},{"field":"summary"},{"field":"technologies"},{"field":"targets"},{"field":"pathways"},{"field":"cancers"},{"field":"drugs"},{"field":"links"}]}]